Verb Surgical

Verb Surgical
ajay_suresh · CC BY 4.0 · source
Name	Verb Surgical
Type	Joint venture
Industry	Medical devices
Founded	2015
Founders	Johnson & Johnson; Verily
Headquarters	United States
Products	Surgical robotics platform
Fate	Operations wound down 2019–2023

Verb Surgical was a joint venture formed to develop advanced surgical robotics combining hardware, software, and cloud-based data analytics for minimally invasive procedures. The company united expertise from Johnson & Johnson and Alphabet Inc.'s life sciences arm Verily to pursue an integrated platform spanning robotic manipulators, imaging, and machine learning. Verb Surgical sought to compete with established firms in the field of robotic surgery and to partner with hospitals, research institutions, and regulatory bodies to drive clinical adoption.

History

The venture was announced in 2015 as a collaboration between Johnson & Johnson's Ethicon division and Verily (then part of Google X and later Alphabet Inc.), building on the histories of Ethicon Endo-Surgery and projects within Google Health. Early leadership drew from executives with backgrounds at Intuitive Surgical, Medtronic, and academic centers such as Mayo Clinic and Cleveland Clinic. Public milestones included prototype demonstrations, strategic hires from Stryker and Zimmer Biomet, and research partnerships with universities like Stanford University and Johns Hopkins University. Press coverage in outlets including The New York Times, The Wall Street Journal, and Reuters tracked the venture as it sought funding rounds and regulatory pathways. By the late 2010s, market consolidation and shifting priorities at parent companies led to restructuring; subsequent reports in trade publications such as FierceBiotech and Stat News documented winding-down activities and asset transfers with mentions of Boston Scientific-era consolidation trends.

Technology and Products

Verb Surgical aimed to integrate robotic manipulators, high-definition imaging, and cloud-based analytics into a cohesive surgical platform. The engineering team referenced developments in kinematic design similar to platforms from Intuitive Surgical and force-feedback research from institutions like MIT and Carnegie Mellon University. Software efforts combined techniques from Google DeepMind research, TensorFlow tooling, and data architectures used at Amazon Web Services to enable intraoperative decision support and post-market surveillance. Prototypes reportedly explored modular arms, wristed instruments, and endoscopic cameras comparable to models used in laparoscopy and thoracic surgery research at Mount Sinai Hospital. Integration work considered interoperability standards promoted by FDA-advising consortia and medical informatics groups including HL7 contributors and academic centers such as University of California, San Francisco.

Clinical Applications and Trials

Verb Surgical targeted minimally invasive specialties including general surgery, gynecology as practiced at centers like Mayo Clinic and Cleveland Clinic, urology procedures similar to those addressed by Intuitive Surgical systems, and thoracic surgery research programs at institutions like Brigham and Women's Hospital. Early-stage feasibility testing emphasized bench studies, cadaver labs at university programs including Johns Hopkins University School of Medicine, and collaboration with clinical investigators who had led trials for devices from Medtronic and Stryker. The company engaged with clinical trial design experts affiliated with NIH-funded networks and consulted regulatory bodies such as the U.S. Food and Drug Administration for pathways used by prior robotic devices. Publicly documented randomized trials or pivotal studies were limited as the platform remained in development when strategic changes shifted priorities at parent companies.

Business Model and Partnerships

Verb Surgical's commercial strategy combined product sales, service contracts, and data-driven subscription offerings to healthcare systems like Kaiser Permanente and academic medical centers. The JV leveraged supply-chain relationships with manufacturers in China and Germany and sought distribution channels through Johnson & Johnson's global networks. Partnerships extended to academic research collaborations with Stanford University School of Medicine and Harvard Medical School investigators, technology alliances with Intel-class chip vendors, and cloud computing collaborations echoing arrangements seen between Microsoft and healthcare startups. Investment and governance structures reflected joint-venture norms seen in deals between General Electric and healthcare divisions, aligning incentives for intellectual property management and commercialization.

Regulatory and Safety Issues

As a developer of surgical robotics, the venture navigated regulatory frameworks administered by the U.S. Food and Drug Administration, European Medicines Agency, and national agencies in markets such as Japan and Australia. Device classification, premarket submissions, and post-market surveillance invoked precedents set by clearances and approvals obtained by companies like Intuitive Surgical and Medtronic. Safety considerations included sensor redundancy inspired by aerospace practices from NASA research, cybersecurity measures paralleling guidance from NIST, and clinical risk analyses modeled after standards from ISO technical committees and IEC safety norms. Public debate in journals such as The Lancet and BMJ covered themes of outcome transparency, surgeon training as in programs at Royal College of Surgeons, and liability frameworks analogous to litigation involving novel implantable devices.

Reception and Impact

The venture attracted attention from investors, clinicians, and policymakers as a potential challenger to established leaders like Intuitive Surgical. Commentators in Forbes, The Economist, and Bloomberg evaluated market implications for hospital procurement strategies and surgeon credentialing at institutions such as Massachusetts General Hospital. Academic commentary in journals associated with Johns Hopkins and Columbia University assessed the research potential of integrating machine learning into intraoperative guidance. Although the platform did not reach widespread clinical deployment before parent-company strategic shifts, the effort influenced conversations on innovation models, public–private partnerships exemplified by collaborations between legacy device makers and tech firms, and the regulatory approaches adopted by agencies like the U.S. Food and Drug Administration for next-generation surgical systems.

Category:Surgical robotics companies